Published Date : Apr 18, 2017
ALBANY, New York, April 18, 2017: MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market study looks into various factors that will influence the growth curve of the global systemic lupus erythematosus (SLE) and lupus nephritis (LN) market through 2025. The reports of this market is presented after a primary research phase, which included collecting data from journals, proprietary databases and secondary research phase that involved collating and scrutinizing the data.
The global SLE and LN market is expected to display a healthy CAGR of 10.6% between 2015 and 2025 for the revenue generation to reach US$3.2 bn by 2025 increasing from US$1.2 bn in 2015. The U.S. is expected to contribute substantially to the growth of the global market. This is due to increased diagnosis of prevalence of SLE and LN and the introduction of three first-in-class pipeline drugs, namely anifrolumab, lupuzor, and orencia. In addition, the availability of three improved therapeutic options in the country is also contributing for double-digit growth rate of the U.S. market for SLE and LN over the forecast period.
Systemic lupus erythematosus (SLE) is an autoimmune disorder that can impact any tissue or organ and is a prototypic autoimmune disorder. SLE is a multi-system disorder that can affect multiple organs in the body. It is heterogeneous in nature, which means no two cases of lupus are alike. However, one of the most severe forms of SLE involves the kidneys, which manifests in the form of lupus nephritis (LN).
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/1045237
At present, the etiology of SLE and LN are partially understood, but genetic and environmental factors have been key reasons for the development of the disease. Till date, the therapy for SLE relies on generic steroids and unspecific immunosuppressive agents. However, both of these therapies are related to severe adverse events and are reasons for mortality and morbidity in lupus.
The report presents answers for several questions that are in the purview of development of therapeutic options for SLE and LN. It includes current status of therapeutic options for SLE and LN and predicts the status of therapeutic options until the end of the forecast period in 2015. The reports of the report is a useful tool for market stakeholders to formulate in-licensing and out-licensing strategies. Market stakeholders can attain this by reviewing pipeline products and technologies and by distinguishing companies with the strongest pipeline.
The report reports helps market stakeholders develop business strategies by a know-how of trends that are shaping and driving the global market for SLE and LN. It also helps market players devise effective sales strategies by receiving insights into the competitive landscape and by examining the growth of various competitors.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org